Latest Ratios: P/E Ratio -126.6x · EV/EBITDA N/A · ROE -16.4%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $10.2B | $1.7B | $2.6B | $1.2B | $1.9B | $5.2B | $3.0B | $656M | — | — | — |
| Enterprise Value | $10.2B | $1.6B | $2.5B | $960M | $1.6B | $4.8B | $2.9B | $617M | — | — | — |
| P/E Ratio → | -126.62 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 27.22 | 4.47 | 8.38 | 4.70 | 9.33 | 39.00 | 33.04 | 12.06 | — | — | — |
| P/B Ratio | 20.81 | 3.56 | 5.55 | 1.85 | 2.41 | 8.89 | 8.85 | 4.31 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.35 | 7.92 | 3.92 | 7.93 | 35.96 | 32.40 | 11.34 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 50.7% | 50.7% | 42.6% | 36.6% | 41.4% | 39.1% | 31.8% | 12.8% | -26.6% | -123.1% | -315.2% |
| Operating Margin | -36.2% | -36.2% | -70.6% | -88.6% | -115.3% | -115.4% | -155.5% | -200.1% | -277.5% | -543.2% | -1924.0% |
| Net Profit Margin | -20.6% | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% | -155.3% | -198.0% | -280.2% | -550.8% | -1943.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.4% | -16.4% | -38.1% | -29.0% | -31.8% | -33.2% | -57.3% | -70.8% | — | — | — |
| ROA | -12.4% | -12.4% | -30.0% | -23.5% | -26.2% | -27.6% | -47.8% | -71.1% | -70.7% | -73.2% | -57.7% |
| ROIC | -26.9% | -26.9% | -43.4% | -34.8% | -51.5% | -50.2% | -53.6% | -72.2% | — | — | — |
| ROCE | -24.9% | -24.9% | -35.4% | -27.6% | -31.1% | -30.5% | -53.9% | -85.7% | -81.4% | -81.2% | -64.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.29 | 0.29 | 0.18 | 0.15 | 0.12 | 0.11 | 0.11 | 0.05 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.10 | -0.30 | -0.31 | -0.36 | -0.69 | -0.17 | -0.26 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -7177.14 | -40692.20 | -2852.43 | -418.69 | -176.32 | -81.98 | -53.07 | -64.23 | -58.10 |
Net cash position: cash ($183M) exceeds total debt ($137M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.64 | 3.64 | 4.88 | 5.79 | 6.58 | 8.67 | 9.29 | 5.28 | 5.16 | 7.16 | 6.80 |
| Quick Ratio | 3.33 | 3.33 | 4.54 | 5.35 | 6.15 | 8.16 | 8.95 | 5.03 | 4.84 | 6.97 | 6.66 |
| Cash Ratio | 2.54 | 2.54 | 3.89 | 4.59 | 5.57 | 7.58 | 8.05 | 4.55 | 4.36 | 6.56 | 6.44 |
| Asset Turnover | — | 0.59 | 0.51 | 0.32 | 0.21 | 0.19 | 0.23 | 0.29 | 0.22 | 0.13 | 0.03 |
| Inventory Turnover | 6.56 | 6.56 | 7.46 | 4.85 | 3.04 | 2.54 | 5.00 | 6.47 | 5.34 | 13.15 | 7.67 |
| Days Sales Outstanding | — | 55.56 | 40.70 | 65.62 | 72.25 | 78.74 | 103.00 | 81.23 | 77.79 | 79.53 | 116.30 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.2% | 0.4% | 0.4% | 0.2% | 0.1% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.2% | 0.4% | 0.4% | 0.2% | 0.1% | 0.0% | — | — | — |
| Shares Outstanding | — | $60M | $58M | $57M | $54M | $48M | $39M | $27M | $27M | $19M | $19M |
Includes 30+ ratios · 10 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TWST stock.
Twist Bioscience Corporation's current P/E ratio is -126.6x. This places it at the 50th percentile of its historical range.
Twist Bioscience Corporation's return on equity (ROE) is -16.4%. The historical average is -39.5%.
Based on historical data, Twist Bioscience Corporation is trading at a P/E of -126.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Twist Bioscience Corporation has 50.7% gross margin and -36.2% operating margin.
Key Metrics
Top Statement Risk
Persistent operating losses and dilution
Metrics are mathematically derived from official filings.
Margin Expansion Stalls at 52%
Gross margin improved to 52.8% in 2026Q3 from 41.0% in 2024Q2, as reported in financial statements, but has plateaued near 52% for three quarters, suggesting scale benefits are not yet fully realized.
The gross margin trajectory shows clear improvement from the 41% level two years ago, but the recent plateau indicates that the high-fixed-cost manufacturing model requires higher utilization to push toward the 60%+ levels of mature peers. Operating margin remains deeply negative at -30.6%, with SG&A consuming 68% of revenue, implying that overhead is scaling with revenue rather than providing operating leverage. The net margin of -29.6% in 2026Q3, excluding the one-time positive quarter in 2025Q3, underscores that the company is still far from profitability.
Returns on Capital Remain Deeply Negative
ROIC has hovered between -5.4% and -17.9% over the past ten quarters, as per reported figures, with no clear trend toward improvement, indicating that the company is not yet generating returns above its cost of capital.
Despite revenue growth, ROIC remains deeply negative, with the latest quarter at -6.4%. The improvement from the -17.9% trough in 2024Q3 is largely due to a one-time gain in 2025Q3 and a slightly larger asset base, not operational efficiency. ROE and ROA follow a similar pattern, with ROE at -7.8% in 2026Q3, reflecting the persistent net losses. The lack of positive returns suggests that the capital invested in the Factory of the Future and R&D is not yet yielding returns, and investors should monitor whether utilization gains can eventually drive ROIC toward positive territory.
Working Capital Cycle Lengthens
Cash conversion cycle extended to 80 days in 2026Q3 from 74 days a year earlier, as per financial statements, driven by a rise in DSO to 50 days and DIO to 56 days, indicating slower cash recovery.
The CCC has been relatively stable around 80 days over the past year, but it remains elevated compared to the 71 days seen in 2025Q2. DSO has increased from 43 to 50 days, suggesting that customers are taking longer to pay, possibly due to a shift in product mix or customer base. DIO has also risen from 43 to 56 days, reflecting higher inventory levels as the company scales production. DPO has improved from 15 to 26 days, indicating that Twist is taking longer to pay suppliers, which may be a deliberate cash management strategy but could strain supplier relationships if extended further.
Minimal Debt but Rising Dependence
Debt-to-equity rose to 0.21 in 2026Q3 from 0.16 in 2024Q2, as reported in SEC filings, though absolute debt remains modest at $93.6M, suggesting a manageable but increasing reliance on borrowings.
Twist's leverage is low in absolute terms, with a D/E of 0.21, but the trend is upward as the company's equity base erodes due to losses. Interest coverage is not calculable for recent quarters due to missing data, but the negative operating income suggests that interest expense, while small, is not covered by operating profits. The company's cash position of $117.4M provides a cushion, but with a net margin of -20.63%, the current cash burn rate implies a limited runway unless the company raises additional capital or achieves profitability sooner than expected.
Liquidity Buffer Thins Rapidly
Current ratio fell to 2.67 in 2026Q3 from 5.51 in 2024Q2, as per balance sheet data, while cash dropped from $243.3M to $117.4M, indicating a shrinking cushion against operational shocks.
The current ratio remains above 2, which is generally considered healthy, but the rapid decline from 5.51 to 2.67 over two years signals that the liquidity buffer is being consumed. The quick ratio of 2.38 suggests that inventory is not a major liquidity concern, but the trend is concerning. With negative free cash flow and a net loss of $35.1M in 2026Q3, the company's ability to weather a prolonged downturn or a delay in achieving profitability is diminishing. Investors should monitor the cash runway closely, as the current burn rate implies a need for additional financing within the next few quarters.
P/S Multiple Misleads on Value
The price-to-sales ratio of 19.13, as reported in valuation data, is often applied to Twist, but it obscures the company's negative margins and high cash burn, making EV/Sales a more appropriate metric.
Twist's P/S ratio of 19.13 appears rich, but it is not directly comparable to profitable peers like Illumina, which trades at a lower multiple. The market often values pre-profit companies on revenue multiples, but this can overstate value if the company's path to profitability is uncertain. A more appropriate metric would be EV/Sales, which accounts for the company's debt and cash position, but even that must be considered alongside the negative operating margin and the need for significant scale to achieve profitability. Investors should focus on the company's ability to convert revenue growth into gross margin expansion and eventually operating leverage, rather than relying solely on P/S.